Blanver

What Blanver does

Blanver is a privately held, for-profit pharmaceutical company headquartered in São Paulo, Brazil, that manufactures and sells medicines. Founded in 1984, the company has operated continuously for approximately four decades and employs between 501 and 1,000 people, indicating a mid-sized manufacturing footprint typical of an established domestic pharmaceutical producer. Its core activity is the production and commercialization of pharmaceutical products for the Brazilian market, though specific therapeutic categories, product lines, dosage forms, and distribution channels are not disclosed in the available source material.

The company's public information surface is extremely thin. Its corporate website (blanver.com.br) returns only a loading/verification page with no substantive content, and aggregated third-party sources provide no data on revenue, ownership, management, product portfolio, customers, certifications, partnerships, regulatory actions, or strategic transactions. Consequently, the business model, revenue mechanics, GTM motion, pricing strategy, and customer segments cannot be characterized from the input. What can be inferred from firmographic data alone is that Blanver operates a manufacturing-led pharmaceutical business at a scale that places it in the established mid-tier of Brazilian industry — large enough to require significant production and quality infrastructure, but lacking the disclosed footprint of Brazil's largest pharma groups.

Name

Blanver

Website

https://blanver.com.br

Company type

Private

Founded year

1984

Headcount range

501–1,000 employees

Short description

Blanver is a privately held Brazilian pharmaceutical company, founded in 1984 and headquartered in São Paulo, that manufactures and sells medicines. It operates as a mid-sized producer with 501–1,000 employees and serves the domestic pharmaceutical market, though no specific products, customer segments, or financial details are publicly disclosed.

Ownership category

akta.pro rank

Product category

Pharmaceutical Manufacturing

NAICS

Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Regulatory Strategy & IND/NDA/BLA Submissions Support (HLAIALAH)

Keywords

• Pharmaceutical manufacturing
• Generic medicines
• Active pharmaceutical ingredients
• Drug formulation
• Human health pharmaceuticals

Headquarters

HQ city

São Paulo

HQ country

Brazil

HQ region

Latin America

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales, Infrastructure

Core offering

Blanver is a Brazilian pharmaceutical company that manufactures and sells medicines. Founded in 1984 and headquartered in São Paulo, Brazil, the company focuses on the production and commercialization of pharmaceutical products for the healthcare market.

Differentiator

Problem solved

Functional benefit

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Direct peers

• Eurofarma Laboratórios: One of Brazil's largest pharmaceutical manufacturers with a broad generics and branded portfolio. Directly comparable to Blanver as a domestic Brazilian pharma manufacturer serving similar retail and institutional channels.
• EMS Pharma: Brazilian pharmaceutical manufacturer with a leading generics portfolio and significant domestic manufacturing capacity. Closely comparable in business model and end markets to Blanver.
• Aché Laboratórios: Brazilian pharma company with branded generics, prescription, and OTC products. Comparable to Blanver as a Brazilian-headquartered manufacturer with overlapping therapeutic categories and distribution channels.
• Hypera Pharma: Largest Brazilian pharma company by market cap with broad branded generics and OTC presence. Comparable to Blanver as a Brazilian pharma manufacturer competing in similar therapeutic areas and channels.
• Laboratório Cristália: Brazilian pharmaceutical manufacturer specializing in hospital, oncology, and specialty products. Comparable to Blanver as a domestically based pharma manufacturer with manufacturing and commercialization under one roof.

Broad incumbents

• Teva Pharmaceutical Industries: Global leader in generics and specialty pharma with manufacturing and commercial operations worldwide. Relevant incumbent peer for Blanver given overlap in generic pharmaceutical manufacturing business model.
• Sandoz: Global generics and biosimilars manufacturer with significant operations in Latin America. Broadly comparable to Blanver as a generics manufacturer with growing presence in Brazil and emerging markets.
• Apotex: Canadian-headquartered generic pharmaceutical manufacturer with global operations. Comparable to Blanver in core manufacturing of generic dosage forms and commercial sales to retail/wholesale channels.

Emerging players

• Aurobindo Pharma: India-based pharmaceutical manufacturer with strong generic and API footprint expanding into Latin America. Comparable to Blanver as a generics manufacturer competing for similar global tenders and emerging-market share.
• Torrent Pharmaceuticals: Indian-headquartered generics and specialty pharma company with international commercial reach. Relevant as an emerging global generics manufacturer pursuing similar growth markets as a Brazil-anchored player like Blanver.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat2 records

Key risks4 records

Key highlights4 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Blanver